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Abstract
Voluntary inspiration breath hold (VIBH) for left breast cancer patients has been
shown to be a safe and effective method of reducing radiation dose to the heart.
Currently, VIBH protocol compliance is monitored visually. In this work, we establish
whether it is possible to gate the delivery of radiation from an Elekta linac using the
Microsoft Kinect version 2 (Kinect v2) depth sensor to measure a patient breathing
signal. This would allow contactless monitoring during VMAT treatment, as an alter-
native to equipment–assisted methods such as active breathing control (ABC).
Breathing traces were acquired from six left breast radiotherapy patients during
VIBH. We developed a gating interface to an Elekta linac, using the depth signal
from a Kinect v2 to control radiation delivery to a programmable motion platform
following patient breathing patterns. Radiation dose to a moving phantom with gat-
ing was veriﬁed using point dose measurements and a Delta4 veriﬁcation phantom.
60 breathing traces were obtained with an acquisition success rate of 100%. Point
dose measurements for gated deliveries to a moving phantom agreed to within
0.5% of ungated delivery to a static phantom using both a conventional and VMAT
treatment plan. Dose measurements with the veriﬁcation phantom showed that
there was a median dose difference of better than 0.5% and a mean (3% 3 mm)
gamma index of 92.6% for gated deliveries when using static phantom data as a ref-
erence. It is possible to use a Kinect v2 device to monitor voluntary breath hold
protocol compliance in a cohort of left breast radiotherapy patients. Furthermore, it
is possible to use the signal from a Kinect v2 to gate an Elekta linac to deliver radia-
tion only during the peak inhale VIBH phase.
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1 | INTRODUCTION
Breast cancer is the most common malignancy in women in the UK,
with more than 40,000 new cases diagnosed each year.1 Surgery fol-
lowed by radiotherapy improves local control and survival such that
rates of local tumor relapse in the breast are now approximately 3%
at 5 yr.2,3 However, breast radiotherapy is also associated with a 1%
increase in nonbreast-cancer-related deaths at 15 yr, 90% of which
are cardiovascular in origin.4,5 Given the increasing incidence of
breast cancer, and the large numbers of survivors in the population,
it is imperative that the improvements in breast cancer mortality are
not compromised by nonbreast-cancer deaths. This may be achieved
by reducing the radiation dose to the heart from radiotherapy. One
approach to achieving this is deep inspiration breath-hold, using
either equipment-assisted or voluntary inspiration breath-hold (VIBH)
techniques.6,7
VIBH techniques are straightforward and cost-effective to imple-
ment, as they use equipment already available in the radiotherapy
treatment room. This includes the ﬁeld light indicators and lasers
used to aid patient setup. The ﬁeld lights or lasers plus skin refer-
ence marks are viewed via CCTV cameras in the control areas and
provide conﬁdence that the patient is holding her/his breath in a
reproducible way during radiotherapy delivery.
More complex approaches to delivering radiotherapy such as
Volumetric Modulated Arc Therapy (VMAT) are likely to become
standard treatments for selected groups of patients.8 There is poten-
tial for the light ﬁelds/lasers to be occluded from view by the gantry
if used for these treatments, which may inhibit visual monitoring of
VIBH, hence requiring equipment-assisted methods to be used. In
addition, the visual monitoring method, whilst shown to be safe and
effective,9 does not allow for automatic gating of the linac in the
event of a sudden patient movement such as a cough. We propose
using the Microsoft Kinect version 2 (Kinect v2) device as a simple,
low cost, noncontact monitoring method as a potential solution.
The Kinect v2 was originally designed as a motion-tracking
peripheral for the Microsoft Xbox One games console. The sensor
contains a standard high deﬁnition (HD) camcorder, an infrared
transmitter and receiver and an array of microphones for positional
sound detection. An infrared time-of-ﬂight (TOF) technique is used
to estimate the distance from the camera to objects in the room.
The Kinect v2 has signiﬁcantly better performance characteristics
than the older Kinect v1 sensor that has been in the literature for
several years, including a higher resolution depth sensor
(512 9 424 vs. 320 9 240), higher resolution color sensor
(1920 9 1080 vs. 640 9 480) and wider ﬁeld of view (70° H, 60°
V vs. 57° H 43° V).
The Kinect v2 has already been used for external head motion
tracking in brain PET scans,10 respiratory motion correction in PET
scans11 and respiratory motion tracking in radiotherapy using a mar-
ker-based system.12 Previous work has shown that the sensor has
distance accuracy and precision of 1 to 2 mm after calibration, which
is sufﬁcient for breath-hold monitoring where changes are 5 to
10 mm in magnitude.10,11,13–15 In our previous work,13 we
demonstrated that the Kinect v2 can be used safely in a radiation
environment without image distortions caused by the radiation
beam. The work reported here can be divided into two components:
1. We performed the ﬁrst clinical study using the Kinect v2 in
breast radiotherapy, with markerless tracking. This was a clinical
feasibility study of observational design. Six breast cancer radio-
therapy patients were monitored in a standard supine treatment
position while performing a VIBH breathing protocol. Distance
information was extracted using the Kinect v2, and used to
obtain breathing traces from the patients.
2. We developed a gating interface to an Elekta linac, using the
depth signal from a Kinect v2 to control the delivery of radiation
to a programmable motion platform. Patient breathing traces
obtained from part 1) were used as movement patterns for the
motion platform, to verify that radiation was correctly delivered
while the gating system was in use.
One aim of this work is to demonstrate that it is possible to
monitor compliance with the VIBH protocol and acquire breathing
traces from patients using the Kinect v2. The second aim is to show
that it is possible to gate radiation delivery based on a signal from a
Kinect v2, derived from patient motion patterns applied to a pro-
grammable motion platform.
2 | MATERIALS AND METHODS
2.A | Clinical study protocol and recruitment
The clinical study design was observational, noninterventional, and
nonrandomized. The study was designed to test the hypothesis that
repeated VIBHs can be monitored with a non contact device (Kinect
v2 system) in a cohort of patients in the supine treatment position
on an angled breast board, on a radiotherapy treatment unit during
the procedure for both standard two ﬁeld whole breast and VMAT
radiotherapy.
The primary end point was the percentage of planned breath
holds for which complete monitoring traces were acquired using
Kinect v2. A complete trace was deﬁned by a sequence of free
breathing, followed by 20 s of breath hold, followed by free breath-
ing. The secondary end point was the percentage of planned breath
holds for which complete traces were acquired at each of the
deﬁned time points of the setup and treatment phases over
the patient cohort. The purpose of this end point was to identify
the time point(s) in the process where failure of data collection
occurred. Figure 1 shows a diagram of the patient pathway used in
this study.
46 monitored breath-holds from ﬁve patients were required for
90% power for an expected 99% success rate, ruling out any rate
<90% at 5% signiﬁcance level. The ﬁnal required sample size of 50
breath holds allowed for any patients who were not willing/able to
hold their breath at any of the time points in the process. The moni-
toring method was considered feasible if there were no more than
one unsuccessful collection of a complete trace. Patients who had
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previously been treated with left breast radiotherapy using a VIBH
breathing protocol as participants in the UK HeartSpare trial were eli-
gible for this feasibility study.6,9 Local and external ethics approval
was obtained from the Leicester South NRES East Midlands Research
Ethics Committee and 10 patients were invited to participate.
2.B | Clinical study experimental setup
A Kinect v2 was setup on a tripod system in an Elekta treatment
bunker as shown in Fig. 2. In previous work, a calibration procedure
for the Kinect v2 was established, and the temperature stability of
the device was investigated.13 The clinical study protocol was then
followed according to Fig. 1, and breath hold data were acquired
using the Kinect v2 sensor. The light ﬁeld was also used to monitor
breath holds visually, as per clinical practice.
To acquire breath hold data from the Kinect v2, custom C++
software was written using the free Kinect for Windows Software
Development Kit (SDK) 2.0 (see Fig. 3). Patient volunteers were
F I G . 1 . Workﬂow diagram for clinical study.
F I G . 2 . Diagram of clinical study experimental setup. A Kinect v2
sensor was connected to a dedicated control laptop in the treatment
room control area using a 12 m USB 3.0 active repeater cable.
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setup on the couch with a breast board, according to the parameters
in their original treatment plans. Two experienced radiographers per-
formed the patient setup procedure. Patients were setup to their
original treatment tattoos, with their peak inhale voluntary breath-
hold position marked on the skin.
2.C. | Gating study
A separate set of experiments was carried out to investigate
whether the depth signal from a Kinect v2 system could be used
to gate an Elekta linac via the previously tested Elekta Response TM
gating interface.16,17 See Fig. 4 for a diagram of the experimental
setup.
Patient breathing traces acquired as described in Section 2.B
were used as input to the motion platform. In order to avoid exceed-
ing the physical constraints of the motion platform, some modiﬁca-
tions to the patient breathing traces were required:
1. A Savitzky-Golay smoothing ﬁlter was applied to avoid velocities
greater than the motion platform’s limit of 3 cm/s.
2. The Kinect v2 measured a 1D signal dKinect, the scalar distance
between the patient’s chest and the sensor. In order to accu-
rately reproduce this signal with the motion platform, it had to
be resolved into a 2D signal to move the platform along its x and
z axes simultaneously. Since the Kinect v2 was angled at 45°
from horizontal during recording, it sufﬁced to use
x; z ¼ dKinect=
ﬃﬃﬃ
2
p
.
3. All amplitudes were reduced by 20% to avoid exceeding the plat-
form’s maximum z axis motion range of 5 cm.
Three situations were investigated:
1. A 200 MU 10 9 10 cm2 single beam delivery for 0.3 min with
the gantry ﬁxed at 0°(ionization chamber point dose in a solid
water phantom).
2. A 250 MU 20 9 20 cm2 simple conformal arc delivery for
0.9 min with the gantry rotating counter- clockwise between
140° and 50° at constant dose rate (ionization chamber point
dose in a solid water phantom).
3. A clinical VMAT plan to treat whole breast and superclavicular
nodes, with a single clockwise arc from 333 to 179 with 484 MU
per fraction. Beam-on time was 1.7 min. The solid water phan-
tom was replaced by a Delta4 4D veriﬁcation phantom [Scandi-
dos, Uppsala, Sweden]. This was to enable a spatial comparison
of dose between ungated delivery to a static phantom, and gated
deliveries using the 2D dose maps provided by the phantom.
For each modiﬁed breathing trace:
1. The motion platform was allowed to move until it reached the
peak inhale position of the ﬁrst breath hold, and was then held
ﬁxed.
2. Couch adjustments were used to move the solid water phantom
surface to 100 cm SSD with the ionization chamber at 5 cm
deep/Delta4 phantom to the clinical plan isocenter.
3. Radiation was delivered with the motion platform in this ﬁxed
reference position, and accumulated charge was recorded using
the electrometer to obtain a reference point dose measurement.
This was repeated three times. (Delta4 reference was obtained
for the clinical VMAT delivery)
F I G . 3 . Screenshot of custom C++ software used to record Kinect
depth data. Software controls for manipulating depth frame data are
shown in the top left (blue rectangle). A patient is visible on the
couch, supported by a breast board. The entire depth frame from
the sensor is recorded at a resolution of 512 9 424 pixels and
frame rate of 30 fps into a lossless binary ﬁle for later analysis. The
user selects a ROI (red rectangle) on the patient’s upper sternum
region, with an area of approximately 300 pixels. The mean distance
from the Kinect v2 to this ROI is then calculated as a function of
time to form a breathing trace signal.
F I G . 4 . Experimental apparatus for gating experiment. A Kinect v2
sensor was setup as in Fig. 2. An in-house, high-precision
programmable motion platform was placed on the treatment couch.
A solid water phantom was positioned on the motion platform, with
a NE2571 Farmer chamber inserted inside. A NE2560 electrometer
was used in conjunction with the Farmer chamber to make point
dose measurements. The control laptop was connected directly to
the linac gating interface using a USB-to-serial connection. For the
Delta4 experiments, the solid water phantom was replaced by a
Delta4 phantom connected to a control PC via an Ethernet
connection.
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4. Our in-house software was used to select a rectangular region of
interest (ROI) with an area of 300 pixels on the surface of the
solid water/Delta4 phantom to obtain dKinect at peak inhale. This
was used to manually select a gating window of dKinect  s mm
using our software. We chose a maximum allowable value of
s = 5 mm to prevent overlap between free breathing and breath
hold signals. When the motion platform moved outside of this
gating window, an inhibit signal was sent by our software to the
linac gating interface over a USB-to-serial connection, preventing
radiation delivery.
5. The motion platform was then reset and allowed to move freely
following the input modiﬁed breathing trace. Radiation was deliv-
ered with gating active. Accumulated charge was recorded using
the electrometer. This was repeated three times.
For each case, the breathing trace acquired from the patients
during simulated VMAT treatment was used for dose veriﬁcation
purposes. Gamma analysis parameters produced by the Delta4 soft-
ware were used to compare ungated with gated doses.
3 | RESULTS
3.A | Clinical study
10 patients were contacted and six responded favorably and partici-
pated in the study. All patient data were collected in a single day.
Both the primary and the secondary end points of the clinical study
were met as traces at all planned time points were successfully
acquired with the Kinect v2, giving a total of 60 breath hold traces.
Figure 5 shows the breathing traces extracted from the Kinect
v2 depth data acquired for a single patient, using three different ROI
selections. It can be seen that the traces are sensitive to the exact
position of the ROI used. Figure 5 also shows all three breathing
traces extracted for patient 6 for the three different gantry positions
recorded. Empirically, the “central” ROI was found to be the most
consistent and easy to locate in the patient depth images, so this
was used for each patient in all further analysis.
3.B | Gating study
See Fig. 6 for an example of Kinect v2-monitored, gated radiation
delivery to the solid water phantom. The Kinect v2 was successfully
able to track the motion platform, and gating signals were sent at
the correct times. See Table 1 for a comparison of accumulated
charge between gated and ungated deliveries. All gated deliveries
agreed with the reference data to within 0.5%, suggesting that radia-
tion was delivered correctly, when the motion phantom was within
the preselected gating window only. Traces from patients 5 and 6
were excluded because it was not possible to complete a successful
radiation delivery with a threshold value s < 5 mm without the linac
terminating due to an extended period of beam inactivity.
Table 2 shows a comparison of dose distributions between gated
and ungated radiation deliveries as measured by the Delta4 system.
In all cases, dose distributions from the static phantom with ungated
delivery were used as a reference point in the Delta4 software, and
the gated dose distributions were compared with these references.
Median dose differences were better than 0.5% in all cases, and the
mean (3% 3 mm) gamma index was 92.6%.
4 | DISCUSSION
As previously reported,13 the Kinect v2 is able to track motion pat-
terns with a root mean squared accuracy of approximately 1.5 mm.
Hardware latency causes a delay between a beam on signal and the
F I G . 5 . Top: Example breathing traces extracted from VMAT data
for patient 6, using three different ROIs, drawn on the left breast,
right breast and central chest region between the breasts
respectively. A 5 9 5 square selection of pixels was used for all
three ROIs. This ﬁgure demonstrates the sensitivity of the extracted
breathing trace to the exact position of the selected ROI. Bottom:
Comparison of breathing traces extracted from breath hold data for
patient 6 using a central ROI. The breath hold data was recorded
with the gantry in the lateral and medial treatment positions, and
while the gantry was rotating to simulate a VMAT treatment. All
breathing traces appear inverted, because dKinect decreases as the
patient inhales and moves closer to the sensor.
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commencement of radiation delivery, and vice versa for beam off.
Previous studies have found beam-on delays ranging between
220 ms18 and nearly 1 s.17 This raises questions about the dosimet-
ric consequences of gating an Elekta linac during free breathing. For-
tunately, for our application, where radiation is delivered only during
breath holds that last approximately 20 s, the impact of this latency
is negligible. This is conﬁrmed by our point dose measurements,
which show agreement between gated and nongated deliveries of
better than 99.5%.
The Delta4 dose distribution data showed a range of agreements
between the gated and ungated radiation deliveries, with the major-
ity being clinically acceptable. This work was a proof of principle,
and an in–depth investigation of the reasons for the variations would
be required if this approach was to be considered for patient
treatment.
In this work, we used a rather large total gating window width of
0.5 cm. In the course of our experiments, we discovered that
dKinect to a completely stationary target could vary by as much as
7 mm as the gantry was rotated during a simulated VMAT delivery.
This is probably due to the infrared scatter from the linac head as it
rotates into the sensor’s ﬁeld of view. With an angular-dependent
calibration, it would be possible to correct the sensor’s output to
take account of this effect. In turn, it would be possible to reduce
the size of the gating window used. A gating window of 2 mm
would be realistic. Colgan et al. showed that measurable movement
from movie loops recorded during treatment in breath hold did not
exceed 3mm and the median displacement was 1.5 mm.9
It is still common not to deﬁne a PTV margin explicitly in stan-
dard whole breast radiotherapy although where this is done margins
are typically 10 mm; for complex treatments (e.g., VMAT for breast
and involved nodes) they may be reduced to 5 mm. A gating win-
dow of 2 mm is reasonable in this context.
In Fig. 5, it can be seen that there is some lack of consistency
for breathing traces recorded for patient 6 during three different
simulated treatments. Either this is a result of natural variations in
the patient’s breathing pattern, or the effect of fatigue following
multiple repeated breath holds in a short time period. This is the
subject of further investigation.
We found that dKinect is very sensitive to the position of the
selected ROI on the patient’s chest. Selecting the ROI poorly leads
to large ﬂuctuations in the measured breath hold signal, which
makes selecting an appropriate gating window challenging. We
found that the optimal ROI position for a stable signal was centrally
on the upper torso, just below the breasts. Currently, this ROI has to
be identiﬁed and drawn manually by the software operator. A
method to deﬁne this ROI automatically is a subject of further
research.
F I G . 6 . Example of Kinect v2-monitored radiation delivery during
breath hold to a motion platform with gating active. Corresponding
beam state signal is also shown.
TAB L E 1 Top: Comparison of gated vs. ungated charge recorded
by electrometer for a 200 MU static beam delivery. Bottom:
Comparison of gated vs. ungated charge recorded by electrometer
for a 250 MU simple conformal arc with a 20 9 20 cm2 ﬁeld size.
Trace
Ungated
charge (nC)
With
gating (nC)
Ratio
(gated/ungated)
1 37.534 37.340 0.995
2 37.508 37.523 1.000
3 37.689 37.745 1.002
4 37.636 37.614 0.999
1 45.248 45.161 0.998
2 45.195 45.164 0.999
3 45.312 45.219 0.998
4 45.229 45.164 0.999
TAB L E 2 Measured dose data from the Delta4 system. Median
dose difference and gamma index (3% 3 mm) are shown. In each
case, the ungated radiation deliveries were used as the reference
data and compared to the gated radiation deliveries, so the
percentages in this table represent percentage agreement between
gated and ungated deliveries. Breathing traces for each patient were
used. One whole breast radiotherapy (WBRT) standard two-ﬁeld
plan is included for comparision with the more complex VMAT
plans. The “free breathing” trace was a sinusoid with an amplitude of
10 mm and period of 1 s. The gamma index result for patient 6 was
poor because this patient had a particularly noisy breathing trace,
which caused the breathing signal to jump in and out of the gating
threshold rapidly.
Plan type Case
Median dose
difference (%) Gamma index (%)
VMAT 1 0.1 98.0
VMAT 2 0.2 100.0
VMAT 3 0.5 80.8
VMAT 4 0.0 98.7
VMAT 5 0.0 95.6
VMAT 6 0.1 68.4
WBRT 1 0.1 99.0
“Free breathing” 0.2 100.0
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The position of the Kinect v2 sensor in the treatment room also
requires optimization. We positioned the sensor on a tripod at the
end of the couch, but a clearer view of the patient’s chest region
may be obtained by mounting the sensor on the ceiling, directly in
front of the gantry above the couch. This may also assist with opti-
mal ROI selection.
In this work, gating signals were triggered using the raw, unﬁl-
tered and unsmoothed breathing trace data. It is possible that noise
in the breathing traces can cause the trace signal to momentarily
enter the gating window and trigger an instantaneous gate on/off
signal at an undesirable point in the breathing cycle. This issue can
be avoided by applying a smoothing ﬁlter to the incoming breathing
signal, or building in a hysteresis function which will only trigger gat-
ing if the signal remains inside the gating window for a predeﬁned
amount of time.
There is already a wide variety of commercial optical and infrared
surface imaging systems available for radiotherapy. These include
VisionRT,19 NDI Polaris20 and C-RAD Catalyst.21 These systems
have beneﬁts both for breath hold control and for patient setup. For
example, they can be used for checking and correcting the relative
positions of the breast and thorax in larger breasted patients.
The main advantage of a commodity depth sensor such as the
Kinect v2 is one of cost, with a sensor, control laptop and all other
hardware required available for around $1,400. The equivalent com-
mercial systems can cost upwards of $250,000. Of course, the
Kinect v2 has not gone through the required regulatory process to
be certiﬁed as a medical device, which may complicate its wide-
spread deployment in a clinical environment. However, it provides a
very cost-effective alternative to the commercial systems for the
purposes of research and development. It could also be used as a
quality assurance tool for gated techniques which are triggered by
other devices. The low cost of the Kinect sensor also makes it fea-
sible to have multiple units installed in the treatment room, which
may allow full 3D reconstructions of the patient’s body surface
contour in the future.
5. | CONCLUSION
We have performed a proof–of–concept study using the Kinect v2
for patient monitoring in radiotherapy, and developed a gating inter-
face using the Kinect v2 to control radiation delivery with an Elekta
linac. It is possible to use a Kinect v2 device to monitor voluntary
breath hold protocol compliance in a cohort of left breast radiother-
apy patients. Furthermore, it is possible to use the signal from a
Kinect v2 to gate an Elekta linac to deliver radiation only during the
peak inhale VIBH phase.
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